Latest Articles
Chemotherapy Combinations and the Phase 3 DUO-E Trial - Cancer Network
Chemotherapy Combinations and the Phase 3 DUO-E Trial Cancer Network
Published: Oct. 24, 2024, 6:32 p.m.
Clinicopathological features of endometriosis‑associated adenocarcinoma of the rectum: A report of two cases.
Endometriosis-associated adenocarcinoma of the rectum is rare and is usually misdiagnosed as colorectal carcinoma or other gynecological tumors. In the current report, the clinicopathological features of endometriosis-associated adenocarcinoma of the …
Published: Aug. 30, 2024, midnight
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - OncLive
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer OncLive
Published: June 24, 2024, 7 a.m.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers
Published: June 20, 2024, 7 a.m.
FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma - AJMC.com Managed Markets Network
FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma AJMC.com Managed Markets Network
Published: June 17, 2024, 7 a.m.
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer - Reuters
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer Reuters
Published: June 17, 2024, 7 a.m.
Adding Immunotherapy to Chemotherapy for Endometrial Cancer - Cleveland Clinic
Adding Immunotherapy to Chemotherapy for Endometrial Cancer Cleveland Clinic
Published: June 13, 2024, 7 a.m.
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy - The ASCO Post
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy The ASCO Post
Published: March 27, 2024, 6:45 p.m.
A clearer view on ovarian clear cell carcinoma.
Ovarian clear cell carcinoma (OCCC) is a less common subtype accounting for approximately 5% of all epithelial ovarian cancers (EOCs). Clinical experience and research findings confirm the remarkable differences in …
Published: Aug. 17, 2021, midnight
Link copied to clipboard!